Evidence map›Paper›PMID 37902245›Full record

ArticleCancer medicine2023

A retrospective study of sentinel lymph node biopsy for skin cancer in Japan: Comparison with breast cancer and evaluation of factors related to its use.

Shogo Wada, Tomone Watanabe, Taisuke Ishii, Yuichi Ichinose, Ryoko Rikitake, Dai Ogata, Eiji Nakano, Kenjiro Namikawa, Naoya Yamazaki, Takahiro Higashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shogo WadaDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-0153-1773
Tomone WatanabeDivision of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Taisuke IshiiDivision of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.ORCID 0000-0002-7601-4295
Yuichi IchinoseDivision of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Ryoko RikitakeDivision of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Dai OgataDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-1335-7100
Eiji NakanoDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-7632-8182
Kenjiro NamikawaDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0003-2763-7346
Naoya YamazakiDepartment of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-9638-0428
Takahiro HigashiDivision of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.ORCID 0000-0002-9933-2106

Funding

The National Cancer Center Research and Development Fund 2013-081The National Cancer Center Research and Development Fund 2022-275The National Cancer Center Research and Development Fund 2023-J-3
6 · The paper itself

Abstract

backgroundSentinel lymph node biopsy (SLNB) underuse has been reported for skin cancers; however, actual performance rates have not been compared. The objective of this study was to investigate the SLNB performance rate in skin cancers covered by health insurance in Japan and compare it with that in breast cancer.

methodsThis was a retrospective study of the SLNB performance rate in SLNB-eligible patients with breast or skin cancer from 2018 to 2019, utilizing a database linked to the Hospital-Based Cancer Registry and Diagnosis Procedure Combination survey. Demographic and tumor characteristics were analyzed using logistic regression.

resultsA total of 71,652 patients were included in this study. SLNB was performed in 86.4% (57,904/67,036) of the patients with breast cancer, 44.7% (694/1552) with melanomas, 3.1% (89/2849) with squamous cell carcinomas (SCCs), and 13.5% (29/215) with Merkel cell carcinomas (MCCs). The performance rate of SLNB was significantly lower for skin cancers than for breast cancers (odds ratio [OR], 0.03; p < 0.001). In addition, the performance rates of SLNB were significantly lower for SCCs and MCCs than for melanomas (SCC: OR, 0.04; p < 0.001; MCC: OR, 0.19; p < 0.001). Factors associated with SLNB performance included age, sex, year of incidence, primary tumor site, T stage, and number of hospital beds.

conclusionsSLNB is underutilized for skin cancer. Further investigation is required to explore the reasons for its underutilization so that it may be implemented more universally.

Indexed as

Breast NeoplasmsCarcinoma, Merkel CellMelanomaSentinel Lymph NodeSkin NeoplasmsFemaleHumansJapanNeoplasm StagingRetrospective StudiesSentinel Lymph Node Biopsybreast cancercancer managementclinical managementmelanomasurgical oncology

Identifiers

PMID37902245
PMCPMC10726788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.